ALTEOGEN Inc. (KOSDAQ:196170)
South Korea flag South Korea · Delayed Price · Currency is KRW
490,000
+1,500 (0.31%)
Jul 18, 2025, 3:30 PM KST

ALTEOGEN Company Description

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.

The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology.

It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer.

The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; and Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial.

ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.

ALTEOGEN Inc.
CountrySouth Korea
Founded2008
IndustryBiotechnology
SectorHealthcare
Employees155
CEOSoon-Jae Park

Contact Details

Address:
62, Yuseong-daero
Daejeon, 34054
South Korea
Phone82 4 2384 8780
Websitealteogen.com

Stock Details

Ticker Symbol196170
ExchangeKOSDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyKRW
ISIN NumberKR7196170005
SIC Code2836

Key Executives

NamePosition
Soon-Jae ParkChief Executive Officer
Hang Yeon KimChief Financial Officer